Alliance A151216 (Lung Cancer)

Alliance A151216 (Lung Cancer)

Es posible que algunos contenidos no estén disponibles en español.

Purpose of this Study

We are doing this study to research the genes of patients with lung cancer that has been or will be removed by surgery for a chance to get treatment in a clinical trial.

Who Can Participate?

Eligibility

Adults 18 years and older who:
  • Have lung cancer that has been removed by surgery or can be removed by surgery
  • Have not received chemotherapy or radiation before surgery
  • Are not pregnant
  • Do not have recurrent lung cancer

Age Range

18-110

Sex/Genders

Male (cisgender)
Female (cisgender)
Non-binary or gender fluid
Transgender male
Transgender female
Looking for Healthy Participants
No

What is Involved?

Description

If you choose to join this study, you will:
  • Answer questionnaires
  • Have blood draws
  • Have tissue samples taken
  • Possibly be eligible to join another clinical trial, depending on the results of your genetic testing
  • Be contacted by the study team every 6 months for 5 years

Locations

Duke University Hospital
Duke Raleigh Hospital
Other

Visit Timing

Weekdays

Compensation

No

Spanish Materials Available

No

Study Details

Full Title

Alliance A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

Principal Investigator

Jeffrey
Crawford

Protocol Number

PRO00057971

NCT ID

NCT02194738

Phase

N/A

Enrollment Status

Open to Enrollment